Faculty & Staff Details
|Name:||Lisa Chastain, Pharm.D., BCPS|
|Position:||Assistant Professor, Ambulatory Care Division, Dallas VA|
|Bio||Dr. Chastain is an Assistant Professor in Ambulatory Care at the Texas Tech University HSC School of Pharmacy, Dallas/Fort Worth Campus. Her practice site is at the Fort Worth Outpatient Clinic with the VA North Texas Health Care System (VANTHCS). At her practice site Dr. Chastain focuses care in drug therapy management in the area of diabetes, hypertension, hyperlipidemia and coronary artery disease. Dr. Chastain has been as DFW Preceptor of the Year (2008-2009) by the students of TTUHSC SOP. Most recently Dr. Chastain was recognized by TTUHSC as the 2012 Excellence in Leadership Distinguished Alumni.
Dr. Chastain received her Bachelor of Science degree in Biology from Baylor University in 2001 and her Doctor of Pharmacy degree from the University of Houston College of Pharmacy in May 2005. Dr. Chastain has since completed both a Pharmacy Practice and Primary Care Specialty Residency with the Veterans Affairs North Texas Medical Center and Texas Tech Health Sciences Center School of Pharmacy in Dallas, Texas from 2005-2007. She also earned her BCPS in 2007. Dr. Chastain is the current Residency Program Director for the ASHP-Accredited PGY2 Ambulatory Care Residency at the Dallas/Fort Worth campus.
Dr. Chastain is an active member of American Society of Health System Pharmacists, American College of Clinical Pharmacy and Texas Society of Health System Pharmacists. Additionally, she is active in the local American Diabetes Association (ADA) where she has helped to organize/manage screenings at local diabetes expos and volunteered at a local ADA camps for the past 6 years. She has served ACCP locally within the DFW chapter as the Membership Chair (2009) and as Secretary (2010) as well as President-Elect for 2011. She has also served ACCP on a national level as an active member of the networking committee of the Endocrine & Metabolism PRN.
Doctor of Pharmacy University of Houston – 2005
Bachelor of Science (Biology) Baylor University – 2001
Texas Registered Pharmacist (Lic # 43519) 2005- present
Board Certified Pharmacotherapy Specialist 2007 – Present
TTUHSC School of Pharmacy – DFW Preceptor of the Year – 2009
TTUHSC Excellence in Leadership Distinguished Alumni - 2012
Peer Reviewed Publications
Edwards KL, Chastain LM, Snodgrass L, Martin A, Busti AJ. Effects of combined use of antiretroviral agents and atypical antipsychotics on lipid parameters. J Antivir Antiretrovir 2011; 3: 034-039.
Greene RS, Rangel RM, Edwards KL, Chastain LM, Brouse SD, Alvarez CA, Collins LJ, Brilakis ES, Banerjee S. Ranolazine for the treatment of refractory angina in a veterans population. Cardiovascular Revascularization Medicine. 2011; In Press
Alvarez CA, Russell NM, Edwards KL, Greene RS, Chastain LM, Weideman R, Busti AJ. Combination thiazolidinedione and fibrate effect on high-density lipoprotein cholesterol (HDL-C) concentration in a Veterans Affairs patient population. J Clin Lipidology 2008;2: 447-52.
Chastain, LM, Bain, Amy, Edwards, KL, Bedimo R, Busti AJ. A retrospective study of the lipid-lowering efficacy and safety of ezetimibe added to hydroxy methylglutarylcoenzyme A reductase therapy in HIV-infected patients with hyperlipidemia. J Clin Lipidology. 2007; 1: 634–9.
Greene RS, Rangel RM, Edwards KL, Chastain LM, Brouse SD, Alvarez CA, Collins LJ, Brilakis ES, Banerjee S. Ranolazine for the treatment of refractory angina in a Veterans population. Pharmacotherapy. 2010;30 (10): 375e. [abstract]. Presented at American College of Clinical Pharmacy Annual Meeting. Austin, TX. October 2010.
Snodgrass LC, Bain AM, Edwards KL, Chastain LM, Bedimo R, Busti AJ. Effects of combined use of antiretroviral agents and atypical antipsychotics on lipid parameters. 2009 National Lipid Association Annual Scientific Session, Miami, Florida.
Nicole M. Russell, Carlos A. Alvarez, Anthony J. Busti, Lisa M. Chastain, Krystal L. Edwards, R. Shane Greene, Rick A. Weideman. Combination Thiazolidinedione (TZD) and Fibrate Effect on High Density Lipoprotein Concentration (HDL-C) Presented at National Lipid Association Annual Scientific Sessions. May 29 – June 1, 2008, Seattle, WA. J Clin Lipidology 2008;2:205.
Chastain LM, Bain AM, Edwards KL, Bedimo R, Busti AJ. A retrospective study of the lipid lowering efficacy and safety of ezetimibe added to HMG-CoA reductase therapy in HIV-infected patients with hyperlipidemia. 2007 American College of Clinical Pharmacy Spring Practice and Research Forum, Memphis, Tennessee.